Key result
LDL cholesterol, hsCRP, and lipoprotein(a) are modifiable and independent biomarkers that provide valuable pathophysiologic information for assessing cardiovascular risk.
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“LDL cholesterol, hsCRP, and lipoprotein(a) are three modifiable and fully independent biomarkers that tell us a great deal about the unique and often different pathophysiologic problems which underlie our patients' individual reasons for being at risk for atherosclerotic disease.”
“However, Hingorani and Wald further argue that screening tests with a hazard ratio across quartiles of less than 2000 have no role in cardiovascular disease prevention, a position at odds with all risk models, biomarkers, and imaging strategies endorsed by the European Society of Cardiology, the American College of Cardiology, and the American Heart Association.”
“The authors claim the findings 'strongly support universal screening for all three biomarkers in primary prevention'. We disagree. It is not often appreciated how strong associations must be to be useful in medical screening.”
This commentary emphasizes the independent value of LDL cholesterol, hsCRP, and lipoprotein(a) in assessing cardiovascular risk and guiding primary prevention.
This commentary refers to ‘Low-density lipoprotein cholesterol, C-reactive protein, and lipoprotein(a) universal one-time screening in primary prevention: the EPIC-Norfolk study’, by J. M. Kraaijenhof et al., https://doi.org/10.1093/eurheartj/ehaf209 and the discussion piece ‘Associations too weak to be useful in screening for cardiovascular disease’, by A. D. Hingorani, https://doi.org/10.1093/eurheartj/ehaf942. We are sympathetic to the view of Hingorani and Wald that application of extremely safe therapies to very broad populations can have significant clinical impact and we have long admired their work related to polypills.1 After all, one of us designed and carried out the large-scale JUPITER trial which demonstrated a 63% reduction in myocardial infarction, a 48% reduction in stroke, a 46% reduction in coronary revascularization, and a 20% reduction in all-cause mortality among primary prevention individuals with low levels of low-density lipoprotein (LDL) cholesterol and elevated high-sensitivity C-reactive protein (hsCRP).2 However, Hingorani and Wald further argue that screening tests with a hazard ratio across quartiles of less than 2000 have no role in cardiovascular disease prevention, a position at odds with all risk models, biomarkers, and imaging strategies endorsed by the European Society of Cardiology, the American College of Cardiology, and the American Heart Association. Nonetheless, we appreciate that Hingorani and Wald openly acknowledge that the contribution of hsCRP to cardiovascular risk is at least as large, if not larger, than that of LDL cholesterol and lipoprotein(a), biomarkers already endorsed for near universal screening in all international guidelines. As we showed in both the Women’s Health Study3 and the Epic-Norfolk Study,4 LDL cholesterol, hsCRP, and lipoprotein(a) are three modifiable and fully independent biomarkers that tell us a great deal about the unique and often different pathophysiologic problems which underlie our patients’ individual reasons for being at risk for atherosclerotic disease.
No takes yet. Share an insight, caveat, or question.
Ridker et al. (2025) conducted an editorial in Cardiovascular disease. Biomarker screening (LDL cholesterol, hsCRP, lipoprotein(a)) was evaluated. LDL cholesterol, hsCRP, and lipoprotein(a) are modifiable and independent biomarkers that provide valuable pathophysiologic information for assessing cardiovascular risk.
Synapse has enriched 10 related papers. Consider them for comparative context: